Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174583 · ClinicalTrials.gov registry record · Phase 1
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
- 20
- Study locations
NCT07174583: Recruiting Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas, sponsored by IDEAYA Biosciences.
NCT07174583 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 208 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174583, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Carcinomas, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Primary Outcome
Incidence of dose-limiting toxicities, incidence and severity AEs and SAEs as measured by CTCAE V5.0.
Conditions Studied
Interventions
- DRUG IDE849
- DRUG durvalumab
- DRUG IDE161
Study Locations (20)
Texas
- The University of Texas MD Anderson Cancer Center Houston, Texas 77030-4000 - Houston
- Oncology Consultants, PA - Houston - Houston
- Next Oncology Dallas - Irving
Florida
- Mayo Clinic Hospital - Florida - Jacksonville
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
Illinois
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine - Chicago
- OSF HealthCare Cancer Institute - Peoria
Michigan
- Trinity Health-IHA Medical Group - Hematology Oncology - Ann Arbor Campus - Ann Arbor
- The Cancer and Hematology Centers - Grand Rapids
New York
- Columbia University Medical Center - Herbert Irving Pavilion - New York
- Weill Cornell Medicine - Cutaneous Oncology and Melanoma Program - New York
Washington
- Swedish Cancer Institute - Seattle
- Seattle Cancer Care Alliance - Seattle
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Georgia
- Piedmont Physicians Medical Oncology - Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2029-05 |
| Phase | Phase 1 |
What NCT07174583 shows while recruiting
NCT07174583 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (10% lower).
The record links to 3 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which IDE849 is the first listed.
NCT07174583 names 20 study sites across 13 states, led by Texas, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT07174583 about?
NCT07174583 is a clinical study titled "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer". This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
What is the current status of trial NCT07174583?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2025-10-14. Estimated completion is 2029-05.
What conditions does trial NCT07174583 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3.
What interventions are being tested in trial NCT07174583?
The interventions under investigation include: IDE849 (DRUG), durvalumab (DRUG), IDE161 (DRUG).
Who is sponsoring clinical trial NCT07174583?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174583 being conducted?
This trial has 20 study locations across Colorado, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07174583's enrollment target sits among peer trials
208 26th of 79 higher than 54 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI